Small-molecule Drugs
Small-molecule Drugs - Related Videos
08:34
A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
0 Views •
Cited by 6 •
2015
A protocol for small molecular drug screening based on in-situ synthesis of ultrasmall fluorescent gold nanoclusters (Au NCs) using drug-loaded protein as template is presented. This method is simple to determine the binding affinity of drugs to a target protein by a visible fluorescent signal emitted from the protein-templated Au NCs.
09:24
Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
0 Views •
Cited by 2 •
2017
A simple and non-destructive technique that measures the average content of drug substances in formulated drug products containing fluorine using low-field fluorine-19 (19F) time-domain (TD) nuclear magnetic resonance (NMR) is presented here. The technique can be applied to the development and manufacturing of drugs in the pharmaceutical industry.
09:39
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
0 Views •
Cited by 6 •
2014
Persistent activation of inhibitory G protein-coupled receptors results in sensitization of adenylyl cyclase signaling. To identify the essential molecular pathways, nonbiased approaches are necessary; however, this strategy requires the development of a scalable cell-based cAMP sensitization assay. Herein, we describe a sensitization assay for small molecule and siRNA screening.
10:05
Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)
0 Views •
Cited by 5 •
2016
Identifying the direct targets of genome-targeting molecules remains a major challenge. To understand how DNA-binding molecules engage the genome, we developed a method that relies on crosslinking of small molecules to isolate chromatin (COSMIC).
10:28
Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
0 Views •
Cited by 6 •
2018
An efficient screening protocol is presented for the identification of small molecules that promote astroglial differentiation in glioblastoma stem cells (GSCs). The assay is based on a stem cell differentiation reporter whereby the expression of the enhanced GFP (eGFP) is driven by the human GFAP promoter.
FAQs
A compound’s chemical structure must complement features of its biological target to alter activity effectively. This interaction can inhibit an enzyme, activate or modify receptor signaling, affect ion-channel behavior, or change interactions involving nucleic-acid-associated proteins. The degree of complementarity helps determine whether the compound engages the intended target and produces a measurable biological response.
Potency describes how effectively a compound influences its target, whereas selectivity concerns whether it preferentially affects that target rather than other biological components. Improving both properties can strengthen the intended response while limiting unintended molecular effects. Chemical optimization therefore considers potency and selectivity together, rather than treating strong activity against one target as sufficient.
A compound must remain sufficiently stable and reach relevant tissues for target engagement to occur. Chemical stability influences whether the active structure persists, while distribution affects where the compound can act. Consequently, a molecule with strong activity in isolation may show limited effectiveness if it does not maintain its structure or reach the biological location containing its target.
Evaluation connects molecular activity with pharmacokinetics, the study of how a compound behaves in the body. Researchers consider whether the molecule reaches relevant tissues, remains available long enough, and interacts with the intended target. These factors help distinguish intrinsic chemical activity from practical effectiveness and guide further optimization of potency, selectivity, stability, and distribution.
The overview identifies infections, cancer, inflammation, and metabolic disorders as major application areas. In each case, compounds are designed to alter biological processes associated with disease rather than serving only as general chemical agents. Their defined structures allow researchers to refine activity and other properties for the biological context relevant to a particular therapeutic objective.
In laboratory biology, these compounds can function as selective probes that perturb a chosen molecular process. By observing how cells or biological systems respond when a target’s activity or interaction changes, researchers can investigate cellular function. This use complements therapeutic development because the same capacity for controlled molecular alteration can reveal relationships between targets and biological outcomes.